Targedys
Edit

Targedys

http://www.targedys.com/
Last activity: 29.11.2022
Active
Categories: Management
TargEDys® met à profit ses connaissances uniques sur l’axe intestin-cerveau pour développer et fabriquer des solutions nutritionnelles et thérapeutiques afin de réguler l’appétit et contrôler les maladies métaboliques.
Nous utilisons le concept de mimétisme moléculaire pour atteindre des cibles pharmacologiques connues avec des métabolites bactériens et petites molécules dérivées.
Mentions
9
Location: France, Normandy, Rouen
Total raised: $10.27M

Investors 2

Funding Rounds 2

DateSeriesAmountInvestors
12.04.2017Series A$3.73M-
14.04.2016Series A$6.53M-

Mentions in press and media 9

DateTitleDescription
29.11.2022TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in GermanyLONGJUMEAU, France, Nov. 29, 2022 /CNW/ -- TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife® Satylia® in Germany. The novel dietary supplement based on the next-generation probio...
29.11.2022TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in GermanyPARIS, Nov. 29, 2022 /PRNewswire/ -- TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife® Satylia® in Germany. The novel dietary supplement based on the next-generation probiotic Ha...
29.11.2022TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in GermanyLONGJUMEAU, France, Nov. 29, 2022 /PRNewswire/ -- TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife® Satylia® in Germany. The novel dietary supplement based on the next-generation...
27.09.2022TargEDys and Inoliva announce they have entered a distribution partnership to bring Satylia® to TurkeyLONGJUMEAU, France, Sept. 27, 2022 /PRNewswire/ -- TargEDys and Inoliva, an affiliate of Abdi Ibrahim, have signed an exclusive marketing and distribution agreement to bring Satylia, a food supplement based on the next-generation probiotic ...
08.06.2021TargEDys announces the publication of the first double-blind, randomized, placebo-controlled clinical trial showing Hafnia alvei's efficacy at an unprecedented level in weight loss and satiety USA - ...
08.06.2021TargEDys announces the publication of the first double-blind, randomized, placebo-controlled clinical trial showing Hafnia alvei's efficacy at an unprecedented level in weight loss and satietyLONGJUMEAU, France, June 8, 2021 /PRNewswire/ -- The French biotech TargEDys specialized in breakthrough microbiome-based solutions announces the publication of its study conducted in 230 overweight adults supplemented for 12 weeks, confirm...
12.04.2017TargEDys Raises Additional €3.5M in Series A FundingTargEDys, a Paris, France-based developer of innovative microbiome-based solutions to regulate the appetite, has raised an additional €3.5m in Series A funding. Zaluvida made the investment which supplements the initial €5.8m raised in Apri...
12.04.2017Term Sheet — Wednesday, April 12IP-NOPE Qualtrics, the Provo, Utah-based enterprise software company famous for bootstrapping in its early years, has raised $180 million in new venture funding, valuing it at $2.5 billion. It’s a surprising move for the 15-year-old company...
14.04.2016TargEDys Raises €5.8M in Series A FundingTargEDys, a Rouen, France-based developer of solutions to regulate appetite, raised €5.8m in Series A funding. The round was led jointly by Seventure Partners, NCI and Pontifax. The company intends to use the funds to launch human clinical ...

Reviews 0

Sign up to leave a review

Sign up Log In